united states: j and j seeks ok for first drug against resistant tb

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update UNITED STATES: J and J Seeks OK for First Drug Against Resistant TB Linda A. Johnson
July 3, 2012

Associated Press (07.02.12) Johnson and Johnson on Monday said it is asking US regulators to approve an experimental drug against multidrug-resistant TB. If approved, J and J’s bedaquiline would be the first new TB drug in more than four decades as well as the first drug specifically for treating MDR TB. Bedaquiline, created by J&J’s Janssen Research and Development unit, has been tested in several hundred MDR TB patients in two mid-stage trials lasting six months. Some patients were followed for 1.5 years. This fall, a late-stage trial will compare bedaquiline in combination with standard therapies for TB against placebo pills plus standard treatments. The trial, which will enroll about 600 patients, also will seek to determine whether resistant TB can be treated in nine months - a big reduction from the 18-24 months currently recommended by the World Health Organization. The company also will apply for regulatory approval of bedaquiline in countries where TB is widespread, said Dr. Wim Pays, Janssen’s head of infectious diseases.

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 OHIO: Phila Health Department HIV Testing Well-Received CONNECTICUT: City's Circle Care Center is a Model for HIV Prevention UNITED STATES: New Compound Excels at Killing Persistent and Drug-Resistant Tuberculosis INDIA: India Faces TB Drug Shortage, Warns International Medical Org ALASKA: After Topping List for Chlamydia Rates, Alaska Seeing Some Improvement Tanzania: Police Abuse, Torture, Impede HIV Services Growing HIV/AIDS awareness in Indonesia's Papua region South Africa: Catastrophe as Eastern Cape drug stock-outs continue Community-led programmes critical to progress on AIDS in Sri Lanka One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs UNITED STATES: New Compound Excels at Killing Persistent and Drug-Resistant Tuberculosis INDIA: India Faces TB Drug Shortage, Warns International Medical Org INDIA: WHO Issues Guide For New TB Drug TEXAS: Texas State Researchers Survey Students on HPV Awareness UNITED STATES: STD Screening Strategies: Urine Not Enough in MSM UNITED STATES: CDC Launches First National HBV Testing Campaign for Asian-Americans and Pacific Islanders South Africa: Catastrophe as Eastern Cape drug stock-outs continue Libya's "growing" drugs/HIV problem UNAIDS welcomes new findings that provide an additional tool for HIV prevention for people who inject drugs Study Shows Pill Prevents H.I.V. Among Drug Addicts
Copyright © 2012 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles. Information in this article was accurate in July 3, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.